A Rat Migraine Model Did Not Establish Long-Term THC Treatment for Patients

forensic toxicology working group members October 29, 2026 Forensic Toxicology

Repeated THC preserved a pain-related response in a female-rat migraine model without the worsening seen after morphine. That preclinical comparison does not establish long-term effectiveness or freedom from medication-overuse headache in human patients.

A model based on activity suppression

Researchers applied an irritant to the dura to produce migraine-like suppression of voluntary wheel running. They compared THC, morphine and vehicle, using restoration of running as a pain-related outcome. The animals could not report headache severity, disability or the symptoms used for a human diagnosis.

Repeated treatment produced different patterns

THC restored running after the irritant and retained that effect after repeated administration. Morphine’s benefit diminished, and prior morphine prolonged the irritant-related suppression compared with THC or vehicle. The authors interpreted the morphine pattern as tolerance and medication-overuse-headache-like behavior.

What the negative THC finding means

The tested THC regimen did not produce that same worsening. It does not demonstrate that every dose, duration or cannabis product is free of headache-related complications. Nor does preserved running on repeated tests establish sustained benefit over months or years.

The translational question

Only female rats and a particular induced-pain model were studied. Movement can be influenced by factors other than pain, making dose and behavioral controls important. The results justify further clinical investigation, but they do not compare THC with established human migraine strategies or validate routine long-term use. A treatment claim must retain the distinction between a promising animal endpoint and demonstrated patient benefit.

Related analysis: evaluating cannabis tolerance claims.